PURPOSE: To verify the geometric accuracy of gated RapidArc treatment using kV images acquired during dose delivery. METHODS AND MATERIALS: Twenty patients were treated using the gated RapidArc technique with a Varian TrueBeam STx linear accelerator. One to 7 metallic fiducial markers were implanted inside or near the tumor target before treatment simulation. For patient setup and treatment verification purposes, the internal target volume (ITV) was created, corresponding to each implanted marker. The gating signal was generated from the Real-time Position Management (RPM) system. At the beginning of each fraction, individualized respiratory gating amplitude thresholds were set based on fluoroscopic image guidance. During the treatment, we acquired kV images immediately before MV beam-on at every breathing cycle, using the on-board imaging system. After the treatment, all implanted markers were detected, and their 3-dimensional (3D) positions in the patient were estimated using software developed in-house. The distance from the marker to the corresponding ITV was calculated for each patient by averaging over all markers and all fractions. RESULTS: The average 3D distance between the markers and their ITVs was 0.8 ± 0.5 mm (range, 0-1.7 mm) and was 2.1 ± 1.2 mm at the 95th percentile (range, 0-3.8 mm). On average, a left-right margin of 0.6 mm, an anterior-posterior margin of 0.8 mm, and a superior-inferior margin of 1.5 mm is required to account for 95% of the intrafraction uncertainty in RPM-based RapidArc gating. CONCLUSION: To our knowledge, this is the first clinical report of intrafraction verification of respiration-gated RapidArc treatment in stereotactic ablative radiation therapy. For some patients, the markers deviated significantly from the ITV by more than 2 mm at the beginning of the MV beam-on. This emphasizes the need for gating techniques with beam-on/-off controlled directly by the actual position of the tumor target instead of external surrogates such as RPM.
PURPOSE: To verify the geometric accuracy of gated RapidArc treatment using kV images acquired during dose delivery. METHODS AND MATERIALS: Twenty patients were treated using the gated RapidArc technique with a Varian TrueBeam STx linear accelerator. One to 7 metallic fiducial markers were implanted inside or near the tumor target before treatment simulation. For patient setup and treatment verification purposes, the internal target volume (ITV) was created, corresponding to each implanted marker. The gating signal was generated from the Real-time Position Management (RPM) system. At the beginning of each fraction, individualized respiratory gating amplitude thresholds were set based on fluoroscopic image guidance. During the treatment, we acquired kV images immediately before MV beam-on at every breathing cycle, using the on-board imaging system. After the treatment, all implanted markers were detected, and their 3-dimensional (3D) positions in the patient were estimated using software developed in-house. The distance from the marker to the corresponding ITV was calculated for each patient by averaging over all markers and all fractions. RESULTS: The average 3D distance between the markers and their ITVs was 0.8 ± 0.5 mm (range, 0-1.7 mm) and was 2.1 ± 1.2 mm at the 95th percentile (range, 0-3.8 mm). On average, a left-right margin of 0.6 mm, an anterior-posterior margin of 0.8 mm, and a superior-inferior margin of 1.5 mm is required to account for 95% of the intrafraction uncertainty in RPM-based RapidArc gating. CONCLUSION: To our knowledge, this is the first clinical report of intrafraction verification of respiration-gated RapidArc treatment in stereotactic ablative radiation therapy. For some patients, the markers deviated significantly from the ITV by more than 2 mm at the beginning of the MV beam-on. This emphasizes the need for gating techniques with beam-on/-off controlled directly by the actual position of the tumor target instead of external surrogates such as RPM.
Authors: Julian C Hong; Yao Yu; Aarti K Rao; Sonja Dieterich; Peter G Maxim; Quynh-Thu Le; Maximilian Diehn; Daniel Y Sze; Nishita Kothary; Billy W Loo Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-01 Impact factor: 7.038
Authors: Achilles J Fakiris; Ronald C McGarry; Constantin T Yiannoutsos; Lech Papiez; Mark Williams; Mark A Henderson; Robert Timmerman Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-27 Impact factor: 7.038
Authors: An Tai; James D Christensen; Elizabeth Gore; Ali Khamene; Thomas Boettger; X Allen Li Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-03 Impact factor: 7.038
Authors: H Shirato; S Shimizu; T Kunieda; K Kitamura; M van Herk; K Kagei; T Nishioka; S Hashimoto; K Fujita; H Aoyama; K Tsuchiya; K Kudo; K Miyasaka Journal: Int J Radiat Oncol Biol Phys Date: 2000-11-01 Impact factor: 7.038
Authors: Alejandra Méndez Romero; Roel Th Zinkstok; Wouter Wunderink; Rob M van Os; Hans Joosten; Yvette Seppenwoolde; Peter J C M Nowak; Rene P Brandwijk; Cornelis Verhoef; Jan N M IJzermans; Peter C Levendag; Ben J M Heijmen Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-20 Impact factor: 7.038
Authors: Priya Jayachandran; A Yuriko Minn; Jacques Van Dam; Jeffrey A Norton; Albert C Koong; Daniel T Chang Journal: Int J Radiat Oncol Biol Phys Date: 2009-10-30 Impact factor: 7.038
Authors: Ruijiang Li; Bin Han; Bowen Meng; Peter G Maxim; Lei Xing; Albert C Koong; Maximilian Diehn; Billy W Loo Journal: Int J Radiat Oncol Biol Phys Date: 2013-10-08 Impact factor: 7.038
Authors: Daniel Zucca Aparicio; Ovidio Hernando Requejo; Miguel Ángel de la Casa de Julián; Carmen Rubio Rodríguez; Pedro Fernández Letón Journal: Rep Pract Oncol Radiother Date: 2019-01-22
Authors: Margie A Hunt; Mark Sonnick; Hai Pham; Rajesh Regmi; Jian-ping Xiong; Daniel Morf; Gig S Mageras; Michael Zelefsky; Pengpeng Zhang Journal: J Appl Clin Med Phys Date: 2016-03-08 Impact factor: 2.102